Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature

Treatment with immune checkpoint inhibitors (ICIs) that target the programmed cell death 1/programmed cell death ligand-1 (PD-1/PD-L1) axis is usually ineffective in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC), either as first-line treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Baglivo, Sara, Mandarano, Martina, Bellezza, Guido, Minotti, Vincenzo, Bonaiti, Angelo, Fischer, Matthias J., Birocchi, Ilaria, Roila, Fausto, Metelli, Niccolò, Ludovini, Vienna, Metro, Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098745/
https://www.ncbi.nlm.nih.gov/pubmed/35066813
http://dx.doi.org/10.1007/s40487-022-00183-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098745/
https://www.ncbi.nlm.nih.gov/pubmed/35066813
http://dx.doi.org/10.1007/s40487-022-00183-7

Ejemplares similares